Predicting toxicities of reactive metabolite-positive drug candidates

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 35-54

  Kalgutkar, Amit S ^a   Dalvie, Deepak ^b  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

ADRs; Adverse drug reactions; Bioactivation; Covalent binding; Cytochrome P450; Electrophile; Glutathione; Hepatotoxicity; Idiosyncratic; Liver microsomes; Precision medicine; Prediction in pharmacology; Structural alert

Indexed keywords

DRUG METABOLITE; DRUG;

ADVERSE DRUG REACTION; COVALENT BOND; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIVER MICROSOME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; ANIMAL; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; METABOLISM; PATIENT SAFETY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ACTIVITY RELATION; TOXICOKINETICS; TOXICOLOGY;

ANIMALS; BIOTRANSFORMATION; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PATIENT SAFETY; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICOKINETICS; TOXICOLOGY;

EID: 84920848626     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124720     Document Type: Review

References (77)

1. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, et al. 2012. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem. 55:4896-933
2. Dobo KL, Obach RS, Luffer-Atlas D, Bercu JP. 2009. A strategy for the risk assessment of human genotoxic metabolites. Chem. Res. Toxicol. 22:348-56
3. Evans DC, Baillie TA. 2005. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Dev. 8:44-50
4. Guengerich FP, MacDonald JS. 2007. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20:344-69
5. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, et al. 2011. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10:292-306
6. Stachulski AV, Baillie TA, Park BK, Obach RS, Dalvie DK, et al. 2013. The generation, detection, and effects of reactive drug metabolites. Med. Res. Rev. 33:985-1080
7. Lucas A, Nolan D, Mallal S. 2007. HLA-B5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 59:591-93
8. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, et al. 2010. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42:711-14
9. Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D, Nevirapine Toxicogenomics Study Team. 2012. Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Pers. Med. 9:773-82
10. Uetrecht J, Naisbitt DJ. 2013. Idiosyncratic adverse drug reactions: current concepts. Pharmacol. Rev. 65:779-808
11. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. 2005. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45:177-202
12. Ng W, Lobach AR, Zhu X, Chen X, Liu F, et al. 2012. Animal models of idiosyncratic drug reactions. Adv. Pharmacol. 63:81-135
13. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17:3-16
14. Argikar UA, Mangold JB, Harriman SP. 2011. Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species. Curr. Top. Med. Chem. 11:419-49
15. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, et al. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6:161-225
16. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, et al. 2011. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24:1345-410
17. Shamovsky I, Ripa L, Blomberg N, Eriksson LA, Hansen P, et al. 2012. Theoretical studies of chemical reactivity ofmetabolically activated forms of aromatic amines towardDNA. Chem. Res. Toxicol. 25:2236-52
18. Liu ZC, Uetrecht JP. 1995. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275:1476-83
19. Gardner I, Leeder JS, Chin T, Zahid N, Uetrecht JP. 1998. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53:999-1008
20. Uetrecht J, Zahid N, Tehim A, Fu JM, Rakhit S. 1997. Structural features associated with reactive metabolite formation in clozapine analogues. Chem. Biol. Interact. 104:117-29
21. Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, et al. 2005. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33:243-53
22. Damsten MC, de Vlieger JS, Niessen WM, Irth H, Vermeulen NP, Commandeur JN. 2008. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome P450s. Chem. Res. Toxicol. 21:2181-87
23. Obach RS, Kalgutkar AS, Ryder TF, Walker GS. 2008. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem. Res. Toxicol. 21:1890-99
24. Davies NM, Skjodt NM. 1999. Clinical pharmacokinetics of meloxicam: A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin. Pharmacokinet. 36:115-26
25. Bell JA, Dallas FA, Jenner WN, Martin LE. 1980. The metabolism of ranitidine in animals and man. Biochem. Soc. Trans. 8:93
26. Diao L, Shu Y, Polli JE. 2010. Uptake of pramipexole by human organic cation transporters. Mol. Pharm. 7:1342-47
27. Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. 2002. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem. Biol. Interact. 142:99-117
28. Thompson CD, Barthen MT, Hopper DW, Miller TA, Quigg M, et al. 1999. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 40:769-76
29. Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ. 2007. The direct thrombin inhibitor ximelagatran/melagatran: A systematic review on clinical applications and an evidence based assessment of risk benefit profile. Exp. Opin. Drug Saf. 6:397-406
30. McKenney JM, Proctor JD, Harris S, Chinchili VM. 1994. A comparison of the efficacy and toxic effects of sustained- versus immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-77
31. Pieper JA. 2003. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am. J. Health Syst. Pharm. 60:S9-14
32. Roecklein BA, Sacks HJ, Mortko H, Stables J. 2007. Fluorofelbamate. Neurotherapeutics 4:97-101
33. Hartz RA, Ahuja VT, Zhuo X, Mattson RJ, Denhart DJ, et al. 2009. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)- 2, 5-dimethylpyridin-3-ylamino]-5-oxo-4, 5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. J. Med. Chem. 52:7653-68
34. Subramanian R, Lee MR, Allen JG, Bourbeau MP, Fotsch C, et al. 2010. Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening. Chem. Res. Toxicol. 23:653-63
35. Kalgutkar AS, Mascitti V, Sharma R, Walker GW, Ryder T, et al. 2011. Intrinsic electrophilicity of a 4-substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine derivative: structural characterization of glutathione conjugates in vitro. Chem. Res. Toxicol. 24:269-78
36. Kalgutkar AR, Ryder TF, Walker GS, Orr ST, Cabral S, et al. 2013. Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2, 1-b]thiazole-based inverse agonists of the ghrelin receptor. Drug Metab. Dispos. 41:1375-88
37. Hagmann WK. 2008. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch. Pharm. 341:405-11
38. Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, et al. 2012. Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients. J. Med. Chem. 55:7021-36
39. Lennernas H. 2003. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42:1141-60
40. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, et al. 2009. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37:1970-77
41. Dansette PM, Libraire J, Bertho G, Mansuy D. 2009. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem. Res. Toxicol. 22:369-73
42. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, et al. 2006. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. USA 103:11069-74
43. Wu G, Vashishtha SC, Erve JC. 2010. Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. Chem. Res. Toxicol. 23:1393-404
44. Haddock RE, Johnson AM, Langley PF, Nelson DR, Pope JA, et al. 1989. Metabolic pathways of paroxetine in animals andman and the comparative pharmacological properties of the metabolites. Acta Psychiatr. Scand. Suppl. 350:24-26
45. Venkatakrishnan K, Obach RS. 2005. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab. Dispos. 33:845-52
46. Zhao SX, Dalvie DK, Kelly JM, Soglia JR, Frederick KS, et al. 2007. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. Chem. Res. Toxicol. 20:1649-57
47. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, et al. 2002. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15:907-14
48. Hucker HB, Stauffer SC, Balletto AJ, White SD, Zacchei AG, Arison BH. 1978. Physiological disposition andmetabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos. 6:659-72
49. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, et al. 2013. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 53:601-10
50. Zhang D, He K, Raghavan N, Wang L, Mitroka J, et al. 2009. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs and humans. Drug Metab. Dispos. 37:1738-48
51. Weinz C, Schwarz T, Kubiza D, Mueck W, Lang D. 2009. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 37:1056-64
52. Stangier J. 2008. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47:285-95
53. Xtandi® [package insert]. Northbrook, IL: Astellas Pharma Inc. ; 2012
54. Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, et al. 2013. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother. Pharmacol. 71:489-501
55. Chowdhury G, Shibata N, Yamazaki H, Guengerich FP. 2014. Human cytochrome P450 oxidation of 5- hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem. Res. Toxicol. 27:147-56
56. Cometriq ® [package insert]. South San Francisco, CA: Exelixis Inc. ; 2012
57. Votrient® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013
58. Iclusig® [package insert]. Cambridge, MA: Ariad Pharmaceuticals Inc. ; 2012
59. Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, et al. 2012. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction. Pharm. Res. 29:1960-76
60. Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. 2013. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J. Clin. Pharmacol. 53:974-81
61. Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, et al. 2012. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin. Ther. 34:221-37
62. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, et al. 2009. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52:3028-38
63. Wang Z, Yang J, Kirk C, Fang Y, Alsina M, et al. 2013. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab. Dispos. 41:230-37
64. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, et al. 2011. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117:6287-96
65. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, Obach RS. 2008. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem. Res. Toxicol. 21:2260-71
66. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. 2008. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21:1814-22
67. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, et al. 2009. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22:357-68
68. Geneve J, Degott C, Letteron P, Tinel M, Descatoire V, et al. 1987. Metabolic activation of the tricyclic antidepressant amineptine: II. Protective role of glutathione against in vitro and in vivo covalent binding. Biochem. Pharmacol. 36:331-37
69. Fromenty B, Pessayre D. 1995. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67:101-54
70. Farid NA, Kurihara A, Wrighton SA. 2010. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50:126-42
71. Plavix® [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2013
72. MekinistTM [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014
73. Bauman JS, Kelly JM, Tripathy S, Zhao SX, Lam WM, et al. 2009. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 22:332-40
74. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, et al. 2012. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 25:1616-32
75. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, et al. 2010. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol. Pharmacol. 78:693-703
76. Didiuk MT, Griffith DA, Benbow JW, Liu KK, Walker DP, et al. 2009. Short-acting 5- (trifluoromethyl)pyrido[4, 3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 19:4555-59
77. Kalgutkar AS, Griffith DA, Ryder T, Sun H, Miao Z, et al. 2010. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4, 3-d]pyrimidin- 4(3H)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chem. Res. Toxicol. 23:1115-26